Table 2.

Studies evaluating statin effects on clinical outcomes in intracerebral hemorrhage

Study	Study design	Number of patients	Statin use	Results
Flint [50]	Retrospective	3481	1194 patients with in-hospital statin use	In-hospital use OR for survival 4.3 (3.5-5.2)
Pan [58]	Retrospective	3218	220 patients with in-hospital statin use	Inpatient use: aOR for good outcome (mRS score of 0-2 at 3 months) 2.3 (1.5-3.4)
Chen [59]	Retrospective	8332	749 patients with statin use within 3 months after ICH	Lower all-cause mortality: aHR, 0.74 (0.60-0.92)
Dowlatshahi [60]	Retrospective	2466	537 with prior statin use	Discontinuation higher rate of poor outcome:mortality: aOR, 1.7 (1.1-2.6)
Tapia-Perez [61]	Retrospective	447	18/63 discontinued	Discontinuation higher risk of death: aHR, 6.9 (2.1-23.1)
Siddiqui [62]	Retrospective	2457	268 discontinued; 423 continued	Continuation lower mortality: aOR, 0.11 (0.03-0.44)
Chung [52]	Retrospective	1416	708 discontinued; 708 continued	Continuation lower mortality: HR, 0.38 (0.26-0.57)
Saliba [51]	Retrospective	1304	75.3% of patients had AAEDD <10 mg/d, 19.0% had AAEDD 0-19.9 mg/d, and 5.7% had AAEDD ≥20 mg/d	Statin use reduced the risk of ICH: 0.62 (0.47-0.81) in those with AAEDD ≥20 mg/d

aOR: adjusted odds ratio; aHR: adjusted hazard ratio; AAEDD: average atorvastatin equivalent daily dose.